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Abstract
Background: Adverse drug reactions in children are an important public health problem. We have undertaken a systematic
review of observational studies in children in three settings: causing admission to hospital, occurring during hospital stay
and occurring in the community. We were particularly interested in understanding how ADRs might be better detected,
assessed and avoided.
Methods and Findings: We searched nineteen electronic databases using a comprehensive search strategy. In total, 102
studies were included. The primary outcome was any clinical event described as an adverse drug reaction to one or more
drugs. Additional information relating to the ADR was collected: associated drug classification; clinical presentation;
associated risk factors; methods used for assessing causality, severity, and avoidability. Seventy one percent (72/102) of
studies assessed causality, and thirty four percent (34/102) performed a severity assessment. Only nineteen studies (19%)
assessed avoidability. Incidence rates for ADRs causing hospital admission ranged from 0.4% to 10.3% of all children (pooled
estimate of 2.9% (2.6%, 3.1%)) and from 0.6% to 16.8% of all children exposed to a drug during hospital stay. Anti-infectives
and anti-epileptics were the most frequently reported therapeutic class associated with ADRs in children admitted to
hospital (17 studies; 12 studies respectively) and children in hospital (24 studies; 14 studies respectively), while anti-
infectives and non-steroidal anti-inflammatory drugs (NSAIDs) were frequently reported as associated with ADRs in
outpatient children (13 studies; 6 studies respectively). Fourteen studies reported rates ranging from 7%–98% of ADRs being
either definitely/possibly avoidable.
Conclusions: There is extensive literature which investigates ADRs in children. Although these studies provide estimates of
incidence in different settings and some indication of the therapeutic classes most frequently associated with ADRs, further
work is needed to address how such ADRs may be prevented.
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Introduction
Adverse drug reactions (ADR) are a major health problem to
the individual as well as for society [1]. The World Health
Organisation’s definition of an ADR is ‘‘a response to a drug
which is noxious, and unintended, and which occurs at doses
normally used in man for prophylaxis, diagnosis or therapy of
disease, or for the modification of physiological function’’ [2]. The
frequent occurrence’ of ADRs in children has been reported in
three previous systematic reviews of observational studies covering
the period from 1966 to 2010 [3,4,5]. The reviews provided
estimates of ADR rates causing hospital admission, in hospitalised
children and in outpatient children and demonstrated that ADRs
in hospitalised children are a considerable problem. Two of the
reviews [4,5] provide data on the clinical presentation of the ADR
and the drugs involved. In addition, the more recent review [5]
provides information on the methods and persons involved in
identifying ADRs.
There are however, a number of limitations to the previous
reviews. Each review [3,4,5] applied a search strategy, using a
limited number of keywords to just two electronic bibliographic
databases - MEDLINE and EMBASE. Importantly, as a
consequence, relevant studies may have been excluded. In
addition, the reviews excluded studies that included adults as well
as children, thus reducing the number of eligible studies, and the
more recent reviews excluded studies that evaluated adverse drug
events (medication errors as well as ADRs).
These reviews do not provide information about the drugs
involved in ADRs or about which methods were used for
detecting, or assessing the causality and subsequent of an ADR
[6]. Establishing the relationship between the drug and suspected
reaction is fundamental to drug safety and being able to determine
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the avoidability [7] of an ADR in order to try to prevent its future
occurrence is crucial to reducing the burden of ADRs.
We therefore undertook this systematic review to provide a
more comprehensive assessment of all relevant studies and to
understanding how ADRs might be better detected, assessed and
avoided.
Methods
Criteria for considering studies for this review
Included studies. Observational studies that estimate the
incidence of ADRs including retrospective and prospective cohort
studies of children.
Excluded studies. Studies which focus on ADRs in relation
to a specific drug (e.g. antibiotics or carbamazepine), clinical
condition (e.g. epilepsy, asthma) or specific clinical presentations of
ADRs (anaphylaxis); case control studies; those carried out
exclusively on a neonatal intensive care unit; studies reporting
medication errors, therapeutic failures, non-compliance,
accidental and intentional poisoning and drug abuse.
Participants. Children as defined by the original study
authors.
Studies included three defined populations: 1) children admitted
to hospital, 2) children in hospital and 3) children within the
community.
Interventions. Exposure to any systemic or topical medicinal
product including herbals and aromatherapy, as defined by
researchers.
Types of outcome measure. Any clinical event described as
an adverse drug reaction or non-avoidable adverse drug event to
an individual or group of drugs.
Search methods for identification of studies
A range of electronic bibliographic databases were searched
(Table 1) using a search strategy of text words and indexing terms
(Table 2). In addition, we examined references in relevant studies
and those cited by previous systematic reviews. Contact with
experts was made to identify other potentially relevant published
and unpublished studies. We did not apply language restrictions to
the search.
Selection of studies
Screening on title, abstract and full publication
stage. Duplicate citations were removed. A study eligibility
screening proforma based on pre-specified inclusion criteria was
used. Two reviewers (RMDS, EG) independently screened each
title and categorised as include, exclude or unsure. The two
independent categorisations for all titles were compared and the
title categorised again following discussion if two reviewers
disagreed. Where there was agreement to exclude, the citation
was excluded at this stage. All other citations were reviewed at
abstract level. This process was repeated and where there was
disagreement, discussion took place between reviewers and
citations were re-categorised. Those with agreement to include
or as unsure were reviewed at full publication level. The process
was repeated at full publication stage. Studies considered as unsure
or included at full publication stage were reviewed by a third
reviewer (JJK). Reasons for exclusion were documented at the
abstract and full paper stage of the screening process.
Checking for correct exclusion at each stage. At title
stage, two reviewers (RMDS, EG) independently viewed the
abstracts for a proportion (2%) of studies excluded. Independent
categorisation were compared (as above). This process was
repeated at abstract stage where a third reviewer (JJK) reviewed
10% of full papers for studies excluded based on abstract. This was
repeated at full publication stage where the same reviewer (JJK)
reviewed 20% of excluded full papers. If any studies were excluded
incorrectly at any stage, additional checking was performed.
Data extraction
We extracted the following data from each study:
1) Study characteristics: country; year completed; duration;
number of sites; design (prospective or retrospective); clinical
setting; number of children.
2) Identification of ADR: definition of ADR, including defini-
tion of drug exposure; incidence definition and calculation
(numerator and denominator, either at patient or episode
level); assessment of causal relationship to drug; person who
assessed and categorised ADRs; any method (e.g. case record
review) or reporting system used (e.g. Yellow Card).
3) Information relating to the ADR: clinical presentation;
associated drug(s)/drug classification; associated risk factors
(including age, gender, polypharmacy); ADR considered
avoidable.
Assessment of methodological quality of included
studies
As we were unable to find a validated assessment tool for
critically appraising observational studies of adverse drug reac-
tions, we developed a quality assessment form specifically for the
review. The following aspects were deemed important when
assessing study quality: study design; methods for identifying
ADRs; methods used to establish the causal relationship between
drug and effect; tools for assessing avoidability of the ADR; and
tools for assessing severity of the ADR. Criteria were graded as yes,
no, unclear, or not reported. Two reviewers (RMDS, EG)
independently assessed methodological quality of each study
(Table 3).
Statistical analysis and data synthesis
For each of the three defined populations; children admitted to
hospital, children in hospital and children within the community, a
forest plot was produced to present the ADR incidence rate and
95% confidence interval for each relevant study. Studies were sub
grouped according to whether the incidence rate was reported at
the patient and/or episode level and whether or not all patients
had been exposed to a drug. Further, for rates reported at the
patient level, a distinction was made between studies that had
included one admission per patient and those that had included
multiple admissions per patient. All results provided per study
were included. Pooled estimates were calculated if the variability in
incidence rates was not considered too large.
Univariate meta-regression was used to determine if study level
characteristics (setting, gender, age, oncology and number of drugs
used) are associated with ADR incidence. Incidence rates for
ADRs causing admission and occurring in hospital, calculated at
the patient level for a single episode were included. Multivariate
meta-regression was not undertaken due to the paucity of
covariate data. Risk factor analyses reported by any study were
collated.
Results
The search was originally undertaken in November 2009 and
retrieved 20 906 potentially relevant citations. An update search
was subsequently performed in October 2010 and retrieved an
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additional 3234 citations. Combining both searches we identified
24 140 potentially relevant citations, of which 5 039 duplicate
citations were removed. Screening at title and abstract stage
excluded a further 18 592 and 251 citations respectively. Full
papers were reviewed and 96 citations met the inclusion criteria.
Agreement between reviewers at each stage of the review is
described in Figure S1. Additional citations were identified
through checking for correct exclusion at each stage (n = 3),
reference checking (n = 13) and personal communication with
authors (n = 5). In total, 117 citations relating to 102 studies were
included in the review (Figure S1).
Included studies
A total of 102 studies (117 citations), were included in the
review. Eighty (80/102) studies described the clinical event as an
ADR. In 10 of these studies, ADR was a category within ‘drug
related’ problems/admissions; three studies described ADRs as
drug induced disease/illness. Sixteen described an ADE where the
non-preventable ADE was the same as our definition and two
studies used the term iatrogenic disease to describe an ADR. Some
studies included multiple settings; 42 studies investigated ADRs as
the cause of admission to hospital, 51 studies investigated ADRs in
the hospital setting, and 36 studies investigated ADRs in the
community setting. Studies included in our review were conducted
in 31 different countries, mostly Europe (40/102) and America
(32/102). The earliest study assessed the year 1964, the latest
assessed years 2008–2009 for causing admission, study size ranged
from 24 children to 39,625 admissions. For studies carried out in
hospital; the earliest study assessed the year 1964, the latest 2009,
study size ranged from 81 children to 64,403 children , and the
earliest study assessed the years 1970–1973, the latest 2007, study
size ranged from 73 children to 47,107 children for community
studies. Characteristics for each individual study are provided in
Table 4.
Assessment of methodological quality of included
studies
All studies, including those that evaluated ADEs, explicitly
stated that they had used either the WHO ADR definition [8] or a
comparable one and that they excluded drug errors. Methodo-
logical features of each individual study are provided in Table 4.
Study design
The majority of studies were carried out prospectively (n = 85;
83%), which included 13 in those causing admission, 26 studies
with the ADR occurring in hospital, 24 in the community, 16 in
hospital and causing admission and 6 in mixed hospital and
community settings. Fourteen studies were carried out retrospec-
tively, which included six causing hospital admission, two in
hospital studies, and four in the community, one causing
admission and in the hospital setting and one the study that
considered ADRs that resulted in any medical care contact. Two
studies (one in hospital, and one in hospital and causing
admission), used both study designs. For the remaining study we
were unable to determine the study design (Table 4).
Persons involved in identifying ADRs
Sixty-four studies reported that a clinician; either a medical
doctor, nurse or pharmacist, was involved in the identification of
ADRs. Thirty studies reported also involving either the child or
parent. Eight studies did not provide information about who
identified the ADRs.
Methods for identifying ADRs
Several methods were used to detect ADRs. Multiple ADR
detection methods were employed in 58/102 studies; these
consisted of a combination of case record review, drug chart
review, laboratory data, computerised ADR reporting system,
Table 1. Databases searched.
Database
MEDLINE via OVID 1950 to October 2010
EMBASE via NHS Evidence Health Information Resource 1980 to October 2010
CINAHL via NHS Evidence Health Information Resources 1981 to October 2010
Science Citation Index (SCI) via ISI Web of Knowledge 1990 to October 2010
Biological Abstracts via OVID 1926 to October 2010
International Pharmaceutical Abstracts (IPA) via OVID 1970 to October 2010
Toxicology Literature Online – via USA National Library of Medicine searched October 2010
Iowa Drug Information Service (IDIS) via University of Iowa 1966 to October 2010
Allied and Complimentary Medicine Database (AMED) via OVID 1985 to October 2010
General Practice Research Database via http://www.gprd.com/home/ 1987 to October 2010
Database of Systematic Reviews (The Cochrane Library) via http://www.thecochranelibrary.com searched October 2010
Database of Abstracts of Reviews of Effects (DARE) via University of York searched October 2010
Health Technology Assessment Programme via http://www.hta.ac.uk/index.shtml searched October 2010
National Institute of Health via http://www.nih.gov/ searched October 2010
European Medicines Agency via http://www.ema.europa.eu/ema searched October 2010
US Food and Drug Administration via http://www.fda.gov/ searched October 2010
Clinicaltrials.gov via http://clinicaltrials.gov/ searched October 2010
Agency for Health and Research Quality via http://www.ahrq.gov/ searched October 2010
Incidence and Prevalence via http://www.dialog.com/proquestdialog searched November 2010
doi:10.1371/journal.pone.0024061.t001
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attendance at ward rounds, and interviewing patients/parents or
clinicians. In thirty-one studies case record review alone was
undertaken. The remaining eleven studies used; parental inter-
views/questionnaires (5 studies), clinical assessments (3 studies),
clinician questionnaires (1 study), ward round (1 study) and a
nationwide computer database (1 study). The remaining study
report did not refer to the methods used.
Studies estimating the proportion of paediatric hospital
admissions related to ADRs
Description of studies. There were 42 studies, where ADRs
have been investigated as the cause of admission to hospital. The
period under study varied widely and ranged from 1 week to 11
years. The majority of studies were described as being performed
in a general paediatric unit or ward (n= 22) [9–29,34]. Four
studies included general medicine [30–33] one study in a hospital
emergency department [35]. Two studies covered general
medicine and a hospital emergency department, [36,37], and
one study an integrated primary care information database [38].
Two studies were performed in the paediatric intensive care setting
[39], one in combination with general paediatrics also [40]. Seven
studies covered a combination of clinical settings [41–47]. The
remaining three studies were performed in dermatology and
venereology [48], Infectious diseases [49] and an isolation ward
[50].
ADR incidence. We do not have ADR incidence rates for
12/42 of these studies as the child only data was not available
(n = 4), data were not split by clinical setting (n = 5), data provided
for ADRs in hospital but not causing admission (n= 2) and data
were provided for the total number of ADRs but not the ADR
Table 2. MEDLINE search strategy.
1st Concept - general terms used to describe the participants - infants and children.
1. exp Child/
2. exp Adolescent/
3. (young adj (person$ or people or adult$ or individual$ or women or woman or men or man)).ti,ab.
4. (child$ or adolescen$ or kid or kids or youth$ or youngster$ or minor or minors or teen$ or juvenile$ or student$ or pupil$ or boy$ or girl$).ti,ab.
5. exp Students/
6. Puberty/
7. Pediatrics/
8. (infan$ or newborn$ or new born$ or baby$ or babies or child$ or schoolchild$ or kid or kids or toddler$ or adoles$ or teen$ or boy$ or girl$ or minor$ or juvenil$ or
youth$ or kindergar$ or nurser$ or puber$ or prepuber$ or pre puber$ or pubescen$ or prepubescen$ or pre pubescen$ or pediatric$ or paediatric$ or schoolage$).ti,ab.
2nd Concept including terms relating to adverse drug reactions
9. side effect$.ti,ab.
10. (drug induced or drug related or drug safety).ti,ab.
11. tolerability.ti,ab.
12. toxicity.ti,ab.
13. Harm$.ti,ab.
14. adrs.ti,ab.
15. (adverse adj2 (effect or effects or reaction or reactions or event or events or outcome or outcomes)).ti,ab.
16. (toxic adj3 (effect$ or reaction$ or event$ or outcome$)).ti,ab.
17. exp product surveillance, postmarketing/ or exp adverse drug reaction reporting systems/ or exp drug toxicity/ or exp abnormalities, drug induced/ or exp drug
hypersensitivity/
3rd Concept – terms relating to the occurrence of ADRs
18. incidence/ or prevalence/
19. (incidence$ or prevalence$ or occurrence or admission$ or admitted or visit$ or hospitalisation or hospitalised or hospitalization or hospitalized).ti,ab.
4th Concept - terms that encompass the intervention
20. (drug$ or pharmaceutical$ or medicin$).ti,ab.
21. Pharmaceutical Preparations/
22. (herbal$ or plant or plants or herb or herbs or aromatherap$ or aroma therap$).ti,ab.
23. Medicine, Chinese Traditional/ or Plant Preparations/ or Plants, Medicinal/ or Plant Extracts/ or Drugs, Chinese Herbal/
24. Aromatherapy/
5th Concept - study design
25. Health Care Surveys/
26. Retrospective Studies/
27. Prospective Studies/
28. Cohort Studies/
29. Observational stud$.ti,ab.
30. (prospectiv$ adj3 review$).ti,ab.
31. (prospectiv$ adj3 stud$).ti,ab.
32. (retrospectiv$ adj3 stud$).ti,ab.
33. (retrospectiv$ adj3 review$).ti,ab.
34. population-based stud$.ti,ab.
35. cohort stud$.ti,ab.
36. incidence stud$.ti,ab.
37. Sn.fs.
38. Ep.fs.
39. monitor$.ti,ab.
40. surveillance.ti,ab.
The terms within each concept were ORed, and then all 5 concepts were combined using the AND Boolean operator. This search strategy was translated as appropriate
for the other databases.
doi:10.1371/journal.pone.0024061.t002
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frequency at the patient or episode level (n = 1). Figure 1 presents
data from all studies that provide incidence rates for ADRs causing
admission to hospital (n = 30). These rates range from 0.4% to
10.3% of children (single admission). One study was an extreme
outlier [20] and if this was excluded we found a reduction in the
upper limit of this range to 4%, and a pooled incidence estimate of
2.9% (2.6%, 3.1%).
Studies estimating the proportion of children
experiencing an ADR during their admission
Description of studies. We have included 51 studies, where
ADRs have been investigated in the hospital setting. The period
under study varied widely and ranged from 1 day to ten years. The
majority of studies where described as being performed in a
general paediatric unit or ward (n = 24) [14,19,20,22–
26,28,34,37,51–54,56–63,85] two of which included intensive
care also [64], [40]. Six studies were performed solely in the
intensive care setting [39,65–69], one of which included general
medicine [70]. Three studies included children on an isolation
ward [71–73]. One study was performed using an integrated
primary care information database [38] and one in an isolation
ward [50]. The remaining thirteen studies covered a combination
of clinical settings [41,43–47,49,74–79].
ADR incidence. We do not have ADR incidence rates for 18/
54 of these studies as the child only data was not available (n= 3),
the data were not split by clinical setting (n= 7), data were provided
for the total number of ADRs but not the ADR frequency at the
patient or episode level (n= 5), data provided for ADRs and ADEs
combined (n= 2), and data provided for ADRs causing admission
but not in hospital (n= 1). Figure 2 presents data from all studies
that provide incidence rates for ADRs in hospital (n= 36). These
estimates range from 0.6% to 16.8% of patients (at a single episode
and with prior drug exposure). A pooled estimate has not been
calculated since the rates are considered too varied.
Studies estimating the incidence of ADRS in outpatient
children
Description of studies. We have included 36 studies, where
ADRs have been investigated in the community setting. The
period under study varied widely and ranged from 1 week to 11
years. The majority of studies where described as being performed
in a hospital outpatient or accident emergency department (n = 21)
[25,25,47,55,78,80–84,86–97]. Nine studies were performed in
general practice [98–106]. The remaining six studies were
performed in an infant care and educational establishment
[107], local community setting [108,109], general practice and
accident and emergency department [37], outpatient population
seeking medical care [110], and after discharge from hospital [26].
ADR incidence. We do not have ADR incidence rates for 19
(19/36) of these studies as the child only data were not available
(n = 10), the data were not split by clinical setting (n = 3), data not
available for the total number of children/visits (n = 4), data were
provided for the total number of ADRs but not the ADR
frequency at the patient or visit level (n = 1) and data were
provided for errors only (n = 1). Figure 3 presents data from studies
that provide incidence rates for ADRs in the community (n = 15).
Two studies were not included in this figure due to their method of
ADR ascertainment,
All Settings
Drugs and clinical presentation associated with
ADR. We do not have information on the drugs involved in
ADRs for 50/102 studies, as the child only data were not available
(37 studies), ADRs were a subset of events looked at and ADR
specific data were not reported (10 studies), and drug data were
not available in the publication (3 studies). For studies that
provided data (52/101) (Table 5); anti-infectives were the drug
class most commonly reported across the three settings.
Proportions ranged from 3.5%–66.6% for causing admission
studies (17 studies); 8.6%–100% for in hospital studies (24 studies);
and 17%–78% for community studies (13 studies). The most
common associated clinical presentations reported were nausea,
vomiting, diarrhoea and skin rash. Anti-epileptics were the second
most common reported drug class in both the causing admission
and in hospital studies; proportions ranging from 0.8%–30% (12
studies); and 3.9%–46.6% (14 studies) respectively. Reported
clinical presentations were ataxia, skin rash, increased fitting, and
drowsiness. Non-steroidal anti-inflammatory drugs (NSAIDs) were
Table 3. Assessment of methodological quality.
Study design
Was the study design clear (prospective, retrospective or combined)? Yes/No/Unclear/Not reported
Methods for identifying ADRs
Were the methods used to identify ADRs described in sufficient detail? Yes/No/Unclear/Not reported
Were data collection methods (case-record review, drug chart review, and laboratory data) clearly
described?
Yes/No/Unclear/Not reported
Were the individuals (clinicians, self-reported, researchers) who identified ADRs clearly described? Yes/No/Unclear/Not reported
Methods for determining causality
Was the process of establishing the causal relationship described in detail? Yes/No/Unclear/Not reported
Were standard methods (validated tool) used in the assessment? Yes/No/Unclear/Not reported
Methods for determining avoidability
Was the assessment process of establishing avoidability described in detail? Yes/No/Unclear/Not reported
Were standard methods (validated tool) used in the assessment? Yes/No/Unclear/Not reported
Methods for determining severity
Was the assessment process of establishing predictability described in detail? Yes/No/Unclear/Not reported
Were standard methods (validated tool) used in the assessment? Yes/No/Unclear/Not reported
doi:10.1371/journal.pone.0024061.t003
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Table 4. Study characteristics.
Causing admission studies
Study Country
Study duration/
design Clinical setting Population
Causality
assessment
Avoidability
assessment
Al-Olah 2008 Saudi Arabia 28 days
Prospective
Causing admission
Emergency
department
Children and adults
Not reported in
publication/unable to
obtain from author
Naranjo Definite preventable and definite non-
preventable defined as 3 evaluators in
agreement; possible preventable and
possible non-preventable 2 in agreement
Classen 1991 USA 18 months
Prospective
Acute care
referral hospital
Children and adults
0–20 years
Naranjo Score
Algorithm
Not reported in publication/unable to
obtain from author
Duczmal 2006 Poland Not reported in
publication/unable
to obtain from author
Retrospective
Paediatric
department
Children
0–15 years
Naranjo Not reported in publication/unable to
obtain from author
Easton 1998 Australia 56 days
Prospective
Medical ward Children
19 weeks –
18 years
Naranjo Score
Algorithm
Schumock and Thornton 1992
Easton-Carter
2004
Australia 22 weeks
Prospective
Specialist pead
teaching hosp and
general regional
teaching hosp
Children
Not reported – 17
years
Dartnell et al 1996 Schumock and Thornton 1992
Gallagher 2010 UK 2 weeks
Prospective
Large tertiary -
paediatric hospital
Children
#18 years
Naranjo Hallas et al 1990
Gallagher 2011 UK 12 month
Prospective
Large tertiary -
paediatric hospital
Children
#18 years
Naranjo
Liverpool Causality
Tool
Hallas et al 1990
Ganeva 2007 Bulgaria 5 years
Prospective
Dermatology and
venereology
Children and adults
6–18 years
Naranjo Score
Algorithm
Not reported in publication/unable
to obtain from author
Hewitt 1995 Australia 4 months
Retrospective
General teaching
hospital
Children and adults
Age not reported
Not reported in
publication/unable to
obtain from author
Not reported in publication/unable
to obtain from author
Ives 1987 US 1 year
Retrospective
Family medicine
inpatient service at
hospital
Children and adults
,20 years
Naranjo Score
Algorithm
Not reported in publication/unable to
obtain from author
Kunac 2009 New
Zealand
12 weeks
Prospective
Paediatric Children
Newborn-16 years
Naranjo Score
Algorithm
Schumock and Thornton 1992
Lamabadusuriya
2003
Sri Lanka 11 months
Prospective
Medical ward Children
Not reported in
publication/unable
to obtain from author
Naranjo Score
Algorithm
Not reported in publication/unable to
obtain from author
Major 1998 Lebanon 6 months
Prospective
Medical, paediatric Children and adults
Up to 19 years
Naranjo Score
Algorithm
Not reported in publication/unable to
obtain from author
McDonnell
2002
US 11 months
Retrospective
University affiliated
teaching hospital
Children and adults
Not reported – 15
years
Naranjo Score
Algorithm
Adapted from Schumock &Thornton
Mitchell 1988 US 11 years
Prospective
Teaching and
community
hospitals
Children
0–15 years
Definite - clear
implicated drug
caused the reaction;
Possible – other
factors might have
caused the reaction.
Not reported in publication/unable to
obtain from author
Pouyanne
2000
France 14 days
Prospective
Medical, Public
hospital
Children and adults
Not reported – 15
years
Not reported in
publication/unable to
obtain from author
Not reported in publication/unable to
obtain from author
Santos
2000
Philippines 3 months
Prospective
Paediatric unit Children
0–18 years
Naranjo Score
Algorithm
Not reported in publication/unable to
obtain from author
Schneeweiss
2002
Germany 2 yrs and 5 months
Prospective
Internal medicine
or emergency
departments of
all hospitals
Children and adults
Age not provided
Begaud et al 1985 Not reported in publication/unable
to obtain from author
Van der Hooft
2006
Netherlands 1 year
Retrospective
Academic and
general hospitals
Children and adults
Not reported 2
,18 years
Not reported in
publication/unable
to obtain from
author
Not reported in
publication/
unable to obtain
from author
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Table 4. Cont.
Causing admission studies
Study Country
Study duration/
design Clinical setting Population
Causality
assessment
Avoidability
assessment
Yosselson-
Superstine 1982
Israel 7 months
Prospective
General paediatric
ward
Children
0–16 years
Seidl et al 1965;
Seidl et al 1966;
Mckenzie 1973;
McKenzie 1976;
Whyte 1977
Not reported in
publication/unable to
obtain from author
In hospital studies
Agarwal et al
2010
USA 4 mths
Retrospective
Paediatric intensive
care
Children
0–13 years
Not reported in
publication/unable
to obtain from
author
ADEs assessed, non preventable = ADR.
Determined by individual sites based on local
interpretations, in general was based on the
premise that the ADE may have been avoidable,
given the appropriate implementation of
evidence-based medicine and/or appropriate
use of available services
Barstow 1988 US 4 month prospective Paediatric units Children and adults
Age not provided
Not reported in
publication/unable
to obtain from
author
Not reported in publication/unable to
obtain from author
Benkirane 2009 Morocco 3 month prospective Intensive care unit Children and adults
Age not provided
Not reported in
publication/unable to
obtain from author
ADEs assessed, non preventable = ADR.
Buckley 2007 US 12 days
Prospective
Paediatric intensive
care
Children
Not reported
2,18
Not reported in
publication/unable
to obtain from
author
ADEs assessed using Bates et al,
non preventable ADE=ADR
Choonara 1984 UK 6 months
Prospective
General paediatric
ward
Children
Not reported in
publication/unable to
obtain from author
Seidl et al 1966 6 avoidable: 3 dose prescribed too high, 1
treatment not necessary, 2 application of
pharmacological principles would have
prevented reactions
Dharnidharka
1993
India 18 months
Prospective
Paediatric unit Children
0–12 years
Stephens et al 1998 Not reported in publication/unable to
obtain from author
Dos Santos
2009
Brazil 2 years
Prospective
General paediatric
ward
Children
1 month–14.4 years
Naranjo Not reported in publication/unable to
obtain from author
dos Santos
2006
Brazil 5 months
Prospective
General paediatric
ward
Children
1 month–14.4 years
WHO Not reported in publication/unable to
obtain from author
Easton-Carter
2003b
Australia 39 weeks
Prospective &
prospective
General paediatric
ward
Children
0–17 years
Naranjo Score
Algorithm
Schumock and Thornton 1992
Farrokhi 2006 Iran 5 months
Prospective
Paediatric surgery Children
0.5 months–11 years
Not reported in
publication/unable to
obtain from author
Not reported in publication/unable to
obtain from author
Gonzalez-
Martin 1998
Chile 1 year
Prospective
Paediatric wards Children
5 days–15 years
Naranjo Score
Algorithm
Naranjo and Busto 1989
Imbs 1999 France I day
Prospective
Departments of
medicine, surgery
and geriatrics
Children and adults
0–19 years
Two members of the
pharmacovigilance
team validated each
ADR.
Not reported in publication/unable
to obtain from author
Jha 2007 Nepal 5 months
Prospective
General paediatric
ward
Children and adults
0–18 years
Naranjo Score
Algorithm
Not reported in publication/unable to
obtain from author
Kaushal 2001 US 36 days
Prospective
General paediatric
ward
Children and adults
Neonates –
teenagers
Naranjo Score
Algorithm
Not reported in publication/unable
to obtain from author
Leach 1998 UK 14 months
Prospective
Regional ICU, a
general medical
ward, cardiac ICU
and cardiac
medical ward
Children
Not reported in
publication/unable
to obtain from
author
Naranjo, Karch and
Lasagna, and
Kramer 1979
Not reported in publication/unable
to obtain from author
Maistrello
1999
Italy 6 months
Prospective
Emergency ward,
Infectivology ward,
general paediatric
ward , Pneumology
ward
Children
0–17 years
Not reported in
publication/unable
to obtain from
author
Not reported in publication/unable
to obtain from author
Mitchell 1979 US 4 years
Prospective
General medical,
oncology, NICU
Children
0–17 years
Not reported in
publication/unable to
obtain from author
Not reported in publication/unable
to obtain from author
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Table 4. Cont.
In hospital studies
Neubert 2004 Germany 8 months
Prospective
Paediatric isolation
ward
Children
5 days–17 years
Naranjo Score
Algorithm
Schumock and Thornton 1992
Neubert 2006 Germany 6 months
Prospective
Paediatric isolation
ward
Children and adults
0–18 years
Naranjo Score
Algorithm
Not reported in publication/unable to obtain
from author
Shockrollah
2009
Iran 3 months
Prospective
ICU Children
2 days–12 years
Not reported in
publication/unable to
obtain from author
Not reported in publication/unable to obtain
from author
Takata 2008a USA 3 months
Retrospective
Paediatric hospitals Children
,18 years
Not reported in
publication/unable to
obtain from author
Assessed but no detail provided, non
preventable ADE =ADR
Takata 2008b USA 6 months
Prospective
Paediatric teaching
hospitals
Children
,18 years
Naranjo Score
Algorithm
Assessed but no detail provided, non
preventable ADE =ADR
Telechea 2010 Uruguay 2 months
Prospective
ICU Children
1 month – 14 years
Karch and Lasagna Not reported in publication/unable to obtain
from author
Turner 1999 UK 13 weeks
Prospective
Surgical ward,
medical ward,
neonatal surgical
ward, cardiac intensive
care unit, general
paediatric intensive
care units
Children
1 day–18 years
Choonara &
Harris 1984
Not reported in publication/unable to obtain
from author
Uppal 2000 India 3 years
Prospective
General paediatric
ward
Children and adults
Not reported in
publication/unable to
obtain from author
Karch and Lasagna Not reported in publication/unable to obtain
from author
Vazquez de la
Villa 1989
Spain 12 months
Prospective
Paediatrics service Children
1–8 years
Naranjo Score
Algorithm
Not reported in publication/unable to obtain
from author
Wang 2007 US 3 months
Prospective
ICU, General
paediatric ward,
NICU
Children
Age not provided
Not reported in
publication/unable to
obtain from author
ADEs assessed, non preventable = ADR
Weiss 2002 Germany 8 months
Prospective
Paediatric
isolation ward
Children
1 month–18 years
adapted Naranjo
(Evans et al 1994)
Avoidable or tolerated – toxicity, drug
interactions, secondary effects.
Unavoidable- idiosyncratic or allergic
reactions and intolerance.
Community studies
Calderon-
Ospina 2008
Colombia 12 days
Prospective
Accident and
Emergency visits
Children and adults
0–20 years
WHO Schumock and Thornton 1992
Campbell 1978 USA 48 months
Prospective
Medical care contacts Children and adults
#20 years
Not reported in
publication/unable to
obtain from author
Not reported in publication/unable to
obtain from author
Cirko-Begovic
1989
Croatia 3 months
Prospective
General paediatric
outpatient unit
Children
0–7 years
Hutchinson 1979 Not reported in publication/unable to
obtain from author
Dennehy 1996 USA 1 month
Retrospective
Emergency
department
Children and adults
#25 years
Strand et al 1990 Considered preventable if avoided through
appropriate prescribing, outpatient
monitoring or patient compliance.
Doval 1981 India Not reported in
publication/unable to
obtain from author
Prospective
Outpatient
department
Children and adults
1 year–20 years
Not reported in
publication/unable to
obtain from author
Not reported in publication/unable to
obtain from author
Easton-Carter
2003a
Australia 18 weeks
Prospective
Emergency
department
Children
#17 years
Dartnell et al 1996 Schumock and Thornton 1992
Horen 2002 France Not reported in
publication/unable
to obtain from author
Prospective
office-based practice Children
0–15 years
Begaud et al 1985 Not reported in publication/unable to
obtain from author
Juntti-Patinen
2006
Finland 6 months
Prospective
Emergency
department visits
Children and adults
Not reported in
publication/unable to
obtain from author
WHO Not reported in publication/unable to
obtain from author
Kaushal 2007 US 2 month blocks
Prospective
Office based practice Children
,21 years
Not reported in
publication/unable to
obtain from author
Not reported in publication/unable to
obtain from author
Knopf 2010 Germany 3 years
Prospective
Non-clinical
community setting
Children
#17 years
WHO Not reported in publication/unable to
obtain from author
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Table 4. Cont.
Community studies
Kramer 1985 Canada 1 year
Prospective
Private group
practice
Children
2 days–18.9 years
Kramer 1979 Highly preventable - realistic nondrug
alternative available; Probably preventable
- safer alternative drug available/lower
dosage; Possibly preventable - Dose might
have been modified; Unpreventable -
would not have changed the choice/dose
of drug.
Kushwaha 1994 India 2 years
Prospective
Department of
paediatrics
Children
0–14 years
Not reported in
publication/unable to
obtain from author
Not reported in publication/unable to
obtain from author
Lemer 2009 USA 10mths
Prospective
Attending GP
practice
Children
#12 years
ADEs assessed, non
preventable = ADR
Not reported in publication/unable to
obtain from author
Lewinski 2010 Germany 3 mths
Prospective
Community
pharmacy
Children and adults
#16 years
Strand et al 1990 Not reported in publication/unable to
obtain from author
Martys 1979 UK 2 years
Prospective
General practice Children and adults
2 months–19 years
Not reported in
publication/unable to
obtain from author
Not reported in publication/unable to
obtain from author
Menniti-
Ippolito 2000
Italy 1 year
Prospective
Family
paediatricians
Children
0–14 years
Not reported in
publication/unable to
obtain from author
Not reported in publication/unable to
obtain from author
Miller 2006 Australia 10 months
Prospective
General practice Children and adults
#14 years
Not reported in
publication/unable to
obtain from author
Thomas & Brennan 2000
Mulroy 1973 UK 1 year
Prospective
General practice Children and adults
#20 years
Not reported in
publication/unable to
obtain from author
Not reported in publication/unable to
obtain from author
Munoz 1998 Spain 25 months
Prospective
Emergency room Children
4 weeks–13 years
Karch and Lasagna Not reported in publication/unable to
obtain from author
Otero Lopez
1999
Spain 6 months
Prospective
Emergency
department
Children and adults
,15 years
Karch-Lasagna
modified algorithm
that use the Spanish
Pharmacovigilance
System.
Schumock and Thornton 1992
Phan 2010 USA 5 mths
Retrospective
Emergency
department
Children
#18 years
Naranjo Not reported in publication/unable to
obtain from author
Planchamp 2009France 6 months
Prospective
Emergency
department
Children
0–18 years
Begaud et al 1985 Olivier et al 2005
Prince 1992 US 4 months
Retrospective
Emergency
department
Children and adults
Age not provided
Michel and Knodel
1986
Not reported in publication/unable to
obtain from author
Rebelo Gomes
2008
Portugal 4 months
Prospective
General paediatric
outpatient unit
Children
Age not provided
Not reported in
publication/unable to
obtain from author
Not reported in publication/unable to
obtain from author
Sanz 1987 Spain 6 months
Prospective
General practice,
outpatient
paediatricians
Children
,14 years
Karch and Lasagna,
Venulet, Dangoumau,
Kramer, Naranjo and
Blanc
Not reported in publication/unable to
obtain from author
Sharma 2007 India 4 months
Prospective
Medicine outpatient
department
Children and adults
0–20 years
WHO Not reported in publication/unable to
obtain from author
Smith 1997 US 1 month
Retrospective
Emergency
department
Children and adults
#18 years
Not reported in
publication/unable to
obtain from author
Not reported in publication/unable to
obtain from author
Stoukides1993 US 6 months
Retrospective
Emergency
department
Children and adults
#20 years
Not reported in
publication/unable to
obtain from author
Not reported in publication/unable to
obtain from author
Valladares 1992 Spain 4 years
Prospective
Ear, nose & throat
outpatient unit
Children and adults
0–14 years
Karch and Lasagna Not reported in publication/unable to
obtain from author
Woods 1987 UK 26 weeks
Prospective
Infant care and
educational
establishments
Children
Not reported in
publication/unable
to obtain from author
Not reported in
publication/unable to
obtain from author
Not reported in publication/unable to
obtain from author
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Table 4. Cont.
Community studies
Zahroui 2010 Morocco 7 months
Prospective
Visits to A&E Children
#16 years
Not reported in
publication/unable to
obtain from author
Not reported in publication/unable to
obtain from author
Combined settings (causing admission & in hospital)
Baniasadi 2008 Iran 12 month prospective Multidisciplinary
hospital
Children and adults
0–18 years
Naranjo Score Algorithm Schumock and Thornton 1992
Bordet 2001 France 18month
prospective
General paediatric
ward
Children and adults
0–20 years
Begaud et al 1985 Not reported in publication/
unable to obtain from author
Fattahi 2005 Iran 5 months
Prospective
Paediatric disease
referral centre,
paediatric infectious
diseases dept
Children
0–14 years
WHO Not reported in publication/
unable to obtain from author
Fincham 1989 USA Not reported in
publication/unable to
obtain from author
Not reported in
publication/unable to
obtain from author
Hospital and private
practice
Children and adults
Age not provided
Not reported in publication/
unable to obtain from author
Not reported in publication/
unable to obtain from author
Gill 1995 UK 28 months
Prospective
Paediatric
intensive care
Children
4 days–16 years
Kramer 1979 Not reported in publication/
unable to obtain from author
Haffner 2005 Germany 91 days; 80 days:
overlap of 52 days
Prospective
ICU, General
paediatric ward,
Department of
Paediatrics
Children
Age not provided
WHO Not reported in publication/
unable to obtain from author
Impicciatore
2002
Italy 9 months
Prospective
Paediatric unit Children
3 months–14 years
WHO - confirmed by author Not reported in publication/
unable to obtain from author
Le 2006 US 10 years
Retrospective
Children’s Hospital Children
0–15 years
Definite; Probable; Possible;
Conditional
Not reported in publication/
unable to obtain from author
Martinez-Mir
1996
Spain 105 days; and 99 days
Prospective
Paediatric hospital;
Paediatric isolation
ward, Lactants B ward
Children
1 month–
24 months
Spanish Drug Surveillance
Scheme (Meyboom 1992)
Not reported in publication/
unable to obtain from author
McKenzie 1973 US 8 months
Prospective
University affiliated
teaching hospital,
paediatric medicine
services
Children
0 – no upper limit
provided
Definite - directly attributable
to drug
Probable - a known direct
relationship Possible - nebulous
aspects which could be
explained by the illness. No
reference provided.
Not reported in publication/
unable to obtain from author
McKenzie 1976 US 3 years
Prospective
University affiliated
teaching hospital
Children
0 – no upper limit
provided
Definite - directly attributable
to drug.
Probable - a known direct
relationship. Possible -
temporally related to drug.
No reference provided.
Not reported in publication/
unable to obtain from author
Oshikoya 2007 Nigeria 3 years
Both
General paediatric
ward
Children
4 months–12 years
Jones 1982 Done but no reference
provided
Ramesh 2003 India 7 months
Prospective
Memorial hospital Children and adults
0–18 years
WHO Not reported in publication/
unable to obtain from author
Seidl 1966 US 3 months
Prospective
General medical
service
Children and adults
#20 years
Documented- confirmatory re-
challenge test or a lab result
indicating the unwanted effect.
Probable - improvement or
cessation of symptoms upon
withdrawal of drug.
Not reported in publication/
unable to obtain from author
Smidt1972 New Zealand 6 months
Prospective
General hospital Children and adults
Not reported in
publication/
unable to obtain
from author
Not reported in publication/
unable to obtain from author
Not reported in publication/
unable to obtain from author
Speranza 2008 Uruguay 1 week
Prospective
Paediatric hospital Children
0–12 years
Karch and Lasagna Not reported in publication/
unable to obtain from author
Van der Hooft
2008
Netherlands 1 year
Retrospective
Integrated Primary
Care Information
Database
Children and adults
Not reported-16
years
WHO Hallas et al 1990
Whyte 1977 UK 10 months
Prospective
Paediatric unit Children
0–12+ (maximum
not stated)
Not reported in publication/
unable to obtain from author
Not reported in publication/
unable to obtain from author
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frequently reported as being associated with ADRs in studies in
children in both the causing admission and outpatient studies,
proportions ranging from 4.1%–25% (9 studies) and 1%–10% (6
studies) respectively. Reported clinical presentations were
cutaneous reactions, haematuria, hypertranspiration, drowsiness,
abdominal pain, aggressiveness and vomiting.
In addition, corticosteroids were commonly reported across the
three settings. Proportions ranging from 5.5%–41.0% for causing
admission studies (7 studies); 1.7%–23.4% for in hospital studies
(10 studies); and 0.05%–5% for community studies (3 studies). The
most common associated clinical presentations reported were
immunosuppression, post-operative bleeding, gastric irritation,
and diarrhoea.
The distribution of drugs implicated in ADRs reflect the
prescribing practices for the individual settings. For example;
vaccines were commonly reported in causing admission studies (7
studies) and community studies (5 studies). Proportions ranged
from 1.7%–20.0% and 9.2%–25% respectively, with rash and
fever being the most common associated clinical presentations.
Cytotoxics were reported in both causing admission (8 studies) and
in hospital studies (7 studies), proportions ranged from 14.2%–
50%, and 1.7%–66.6% respectively. The remaining studies
reported a variety of drugs implicated in ADRs, for some more
than one drug was the cause of a single ADR (Table 5).
Meta-regression
Univariate meta-regression results (Table 6) suggest that the
incidence rate for ADRs occurring in hospital is higher than for
ADRs causing admission (OR=2.73 (0.93, 8.03)). In addition, the
results suggest that the incidence rate is higher for studies with a
relatively high mean/median number of drugs per patient
(OR=1.49 (1.14, 1.94)), high percentage of females (OR=1.13
(0.91, 1.40)), high percentage of oncology patients (OR=1.15
(0.89, 1.50)) and low mean age of patients (OR=0.71 (0.39, 1.27)).
However, only the variable representing the mean/median
number of drugs per patient achieves statistical significance.
Risk factors
Risk factor analyses reported by all studies were collated.
Consistent with the meta-regression results, evidence is provided,
from 10/19 studies that consider gender as a risk factor, that boys
are less likely to have an ADR, and, from 16/17 studies, that risk
increases with the number of drugs taken. In addition, 3/3 studies
suggest that the risk of ADRs is greater with off-label use. Only two
studies considered oncology as a risk factor. The results for the age
analyses do not follow a clear pattern and are difficult to interpret
due to the variety of age categorisations used.
Tools for assessing causality
Nearly three quarters of the studies (72/102) mentioned a
causality assessment, of which the Naranjo algorithm was the most
frequently used tool (30/72). Of the 72 studies, seven used a self-
assessment method rather than a published causality tool. Despite
the majority of studies mentioning a causality assessment, only half
of these studies (36/72) reported causality data that were complete
for all identified ADRs, specific to the paediatric population and
did not include errors as part of the assessment (Table 4).
Tools for assessing severity
Thirty-four (34/102) studies performed anADR severity assessment.
Rates ranged from 0%–66.7% of reported ADRs considered to be
severe. By setting, the proportion of ADRs occurring in hospital
assessed as severe ranged from 0% to 66.7%, compared with 0% to
45.5% of ADRs causing admission, and 0% to 32.6% of ADRs
occurring in the community. Twenty studies provided a reference to
indicate the severity tools used, however tools differed widely.
Examples of ADRs assessed as severe were those that caused death
or were directly life-threatening, caused hospital admission, prolonged
hospitalisation or caused transfer to higher level of clinical care.
Assessment of avoidability
Nineteen (19/101) studies performed an avoidability assess-
ment, however, data were only available for 14/19 studies as child
only data were not available in 4/19 and ADR specific data were
not provided in 1/19. For these 14 studies 7%–98% of ADRs were
designated either definitely/possibly avoidable. Three studies
provided the rationale for sixty-two avoidable ADRS; inappropri-
ate selection or indication for use of drug (n= 14), inadequate
patient education (n= 14), prescribing not rationale (n = 11), lack
of appropriate prophylaxis for known ADR (n= 9), lack of
appropriate monitoring of drugs (n = 5), previous known ADR to
medication (n = 3), dose prescribed was too high (n= 3),
inappropriate duration of treatment (n = 1), drug was not
prescribed per treatment protocol (n = 1), inappropriate duration
of drug and monitoring of treatment (n = 1). Ten studies used a
recognised avoidability assessment; of which half used Schumock
and Thornton [111] (Table 4).
Combined settings (in hospital & in community)
Doomra 2001 India 15 months
Prospective
General paediatric
outpatient unit
Children and adults
0–19 years
Naranjo Score
Algorithm
Not reported in publication/unable to obtain from
author
Combined settings (causing admission, in hospital & community)
Al-Tajir 2005 United
Arab
Emirates
12 month
prospective
General paediatric
ward
Children and adults
,15 years
Naranjo Score
Algorithm
Schumock and Thornton 1992
Buajordet 2002 Norway 5 month
prospective
General paediatric
ward
Children
0–16 years
Naranjo Score
Algorithm
Not reported in publication/unable to obtain from
author
Jonville-Bera
2002
France 1 week
Prospective
Paediatric wards, A&E,
private paediatricians
Children
Age not provided
Begaud et al 1985 Not reported in publication/unable to obtain from
author
Jose and Padma
2006
India 12 months
Prospective
Various departments
(not stated)
Children and adults
0–15 years
Naranjo Score
Algorithm
Lau et al 2003
doi:10.1371/journal.pone.0024061.t004
Table 4. Cont.
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Figure 1. What proportion of all paediatric hospital admissions are ADR related?
doi:10.1371/journal.pone.0024061.g001
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Figure 2. What proportion of children in hospital experience an ADR during their admission?
doi:10.1371/journal.pone.0024061.g002
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Discussion
This is the largest systematic review of ADRs in children to date
and shows clearly that ADRs are an important clinical problem for
children and have been the subject of a large number of studies.
Unlike previous systematic reviews [3,4,5], our review searched
for studies using a comprehensive search strategy of a large
number of databases, including those specific to toxicology and
pharmacology. Nineteen databases were searched of which eight
retrieved eligible studies. When compared with the previous
reviews this resulted in an additional 73 studies being included in
our review, of which, in 24, we were able to extract data. We
included studies where ADEs had been evaluated, and that
included both adults and children. In addition, we contacted
authors of studies to obtain unpublished information. As a result,
we were able to obtain unreported ADR incidence data for an
additional 24/102 studies. This allowed us to make a more
informed judgement regarding ADR incidence estimates.
In agreement with previous studies, including those specific to
adults [112], this review found that ADR incidence rates were
generally higher in hospitalised children than ADR rates causing
hospital admission or in an outpatient setting. One of the main
difficulties when comparing ADR incidence rates, particularly
from observational studies, is that the studies differ in a number of
ways, such as clinical setting, population characteristics and study
duration. This may explain the large variation in the incidence
rates reported. However, since the numerators and denominators
used to calculate ADR incidence were not consistent across studies
it was not possible to apply statistical methods to comprehensively
explore the heterogeneity. Due to the large amount of heteroge-
neity, a pooled estimate of the incidence rate has been provided for
ADRs causing admission only.
Concerning risk factors associated with ADRs, we found
evidence, from both univariate meta-regression and the collation
of risk factor analyses from individual studies, that the use of
multiple drugs is an important predictor of ADRs. This may be
due to the additive risk of an ADR when receiving several drugs or
to drug-drug interactions.
We report where possible the drugs associated with ADRs and
the clinical presentation, although information regarding drugs
involved was poorly reported. The types of drugs associated with
ADRs differed substantially between studies due to differences
between patient populations there were a number of similarities,
and many of the drugs analysed in this review are commonly used
in children. The results of this review will facilitate a greater
understanding of prescribing practices, thus ultimately reduce
drug harm. This may help in the development of interventions to
improve drug prescribing and monitoring.
We examined the methods used for detecting, and assessing the
causality, severity and avoidability of an ADR. The assessment of
Figure 3. What proportion of outpatient children experience ADRs?
doi:10.1371/journal.pone.0024061.g003
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Table 5. Drug class and clinical presentation of ADRs.
Causing admission studies
Drug class Study
Population of
study
Total number of
ADRs reported in
study
Number of ADRs
due to drug class
(%) Clinical presentation
Anti-infectives
(n- =16)
Easton (1998) 1682 admissions 10 1 (10%) Colitis, ileus
Impicciatore (2002) 116 children 12 4 (33.3%) Urticaria, periorbital oedema, neutropenia
Lamababusuriya (2003) 39625 admissions 63 38 (60.3%) Erythema multiforme, stevens-johnson
syndrome, rash, raised intracranial pressure
Oshikoya (2007) 3821 children 17 7 (41.1%) Provided for deaths only61
Easton Carter (2004) 2933 admissions 29 Not reported in
publication
Not reported in publication
Mitchell (1988) 7271 children 288 10 (3.5%) Diarrhoea, fever, erythema multiforme death
62
Major (1998) 457 children 26 6 (23%) Not reported in publication
Santos (2000) 624 children 14 6 (42.8%) Not reported in publication
Gallagher (2010) 462 children 18 3 (16.6%) Diarrhoea
Duczmal (2006) 4996 admissions 58 Not reported in
publication
Not reported in publication
Ganeva (2007) 73 children 6 4 (66.6%) Not reported in publication
Fattahi (2005) 404 children 9 4 (44.4%) Not reported in publication
Martinez-Mir (1996) 490 children 21 10 (47.6%) Not reported in publication
Yosselson-Superstine (1982) 906 children 29 Not reported in
publication
Not reported in publication
McKenzie (1976) 3556 admissions 72 Not reported in
publication
Provided for deaths only62
Gallagher (2011) 6821 children 249 16 (6.4%) Diarrhoea, Rash, Vomiting, Lip swelling,
Deranged LFTs, Thrush
Anti-epileptics
(n=12)
Easton (1998) 1682 admissions 10 3 (30%) Increased fitting, Rash, aphasia/motor
regression
Impicciatore (2002) 116 children 12 2 (16.6%) coma
Lamababusuriya (2003) 39625 admissions 63 4 (6.3%) Ataxia and cerebellar signs, liver failure,
stevens-johnson syndrome
Oshikoya (2007) 3821 children 17 1 (5.8%) Not reported in publication
Mitchell (1988) 7271 children 288 23 (7.9%) Lethargy, ataxia, rash, erythema
Anti-epileptics
Le (2006) 64 403 admissions 35 Not reported in
publication
Not reported in publication
Santos (2000) 624 children 14 1 (7.1%) Not reported in publication
Yosselson-Superstine (1982) 906 children 29 Not reported in
publication
Not reported in publication
McKenzie (1976) 3556 admissions 72 Not reported in
publication
Not reported in publication
Fattahi (2005) 404 children 9 1 (11.1%) Not reported in publication
Jonville-Bera (2002) 260 children 4 1 (25%) Convulsion
Gallagher (2011) 6821 children 249 2 (0.8%) Constipation, respiratory depression
NSAIDS
(n=9)
Duczmal (2006) 4996 admissions 58 Not reported in
publication
Not reported in publication
Impicciatore (2002) 116 children 12 1 (8.3%) Coma
Lamababusuriya (2003) 39625 admissions 63 3 (4.7%) Rectal bleeding, Aspirin – Reye syndrome
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Table 5. Cont.
Causing admission studies
Drug class Study
Population of
study
Total number of
ADRs reported in
study
Number of ADRs
due to drug class
(%) Clinical presentation
Major (1998) 457 children 26 2 (7.6%) Not reported in publication
Gill (1995) 909 admissions 10 1 (10%) Not reported in publication
Gallagher (2011) 6821 children 249 31 (12.4%) Post-op bleeding, haematemesis,
constipation, abdominal pain
Gallagher (2010) 462 children 18 1 (5.5%) Haematemesis
Mitchell (1988) 7271 children 288 12 (4.1%) Gastritis
Jonville-Bera (2002) 260 children 4 1 (25%) Melaena
Cytotoxics
(n=8)
Mitchell (1988) 7271 children 288 Not reported in
publication
Deaths62
Major (1998) 457 children 26 10 (38.4%) Not reported in publication
Santos (2000) 624 children 14 2 (14.2%) Not reported in publication
Yosselson-Superstine (1982) 906 children 29 Not reported in
publication
Death61
McKenzie (1976) 3556 admissions 72 Not reported in
publication
Provided for deaths only63
Fattahi (2005) 404 children 9 2 (22.2%) Not reported in publication
Gallagher (2010) 6821 children 249 110 (44.2%) Thrombocytopenia, Anaemia, Vomiting,
Mucositis, Deranged LFTs,
Immunosuppression, Diarrhoea, Nausea,
Constipation, Headache, Abdominal pain,
Back pain, Haematuria, Leukencephalopathy,
Deranged renal function
Gallagher (2010) 462 children 18 9 (50%) Pyrexia, neutropenia, lethargy, decreased
responsiveness, vomiting
Corticosteroids
(n=7)
Easton (1998) 1682 admissions 10 1 (10%) Unstable diabetes
Santos (2000) 624 children 14 1 (7.1%) Upper GI bleed
Yosselson-Superstine (1982) 906 children 29 Not reported in
publication
Not reported in publication
McKenzie (1976) 3556 admissions 72 Not reported in
publication
Not reported in publication
Ganeva (2007) 73 children 6 2 (33.3%) Not reported in publication
Gallagher (2010) 6821 children 249 102 (41.0%) Immunosuppression, Post-op bleeding,
Hyperglycaemia, Hypertension, Gastritis,
Increased appetite, Impaired healing, adrenal
suppression
Gallagher (2010) 462 children 18 1 (5.5%) Vomiting
Vaccines
(n=7)
Easton (1998) 1682 admissions 10 1 (10%) Hypotonic-hyporesponsive episode
Lamababusuriya (2003) 39625 admissions 63 9 (14.2%) Rash, encephalopathy, fits, head lag
Easton Carter (2004) 2933 admissions 29 Not reported in
publication
Not reported in publication
Mitchell (1988) 7271 children 288 5 (1.7%) Not reported in publication
Santos (2000) 624 children 14 1 (7.1%) Not reported in publication
Gill (1995) 909 admissions 10 2 (20%) Seizures, fever
Gallagher (2010) 6821 children 142 Fever, Rash, Irritability , Seizure , Vomiting,
Pallor, Apnoea , Limb swelling, Lethargy ,
Thrombocytopenia Diarrhoea, Abdominal
pain, Respiratory distress, Kawasaki disease
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In hospital studies
Anti-infectives
(n=24)
Al-Tajir (2005) 2351 episodes 2 2 (100%) Not reported in publication
Baniasadi (2008) 693 children 27 Not reported in
publication
Not reported in publication
Choonara (1984) 268 children 15 5 (33.3%) Vomiting, oral monilia, diarrhoea
Dharnidharka (1993) 703 children 7 1 (14.2%) Skin rash
Dos Santos (2006) 265 children 47 18 (38.2%) Not reported in publication
Dos Santos (2009) 3726 episodes 302 57 (18.8%) Not reported in publication
Easton Carter (2003b) 17432 episodes 41 Not reported in
publication
Not reported in publication
Farrokhi (2006) 81 children 3 1(33.3%) Not reported in publication
Fattahi (2005) 380 children 40 35 (87.5%) Not reported in publication
Gill (1995) 899 episodes 76 15 (19.7%) Not reported in publication
Gonzalez-Martin (1998) 219 children 46 4 (8.6%) Not reported in publication
Jha (2007) 943 children 13 12 (92.3%) Macupapular rashes, vomiting, diarrhoea,
drug fever
Jonville-Bera (2002) 227 children 6 2 (33.3%) Diarrhoea, rash
Impicciatore (2002) 1619 children 29 9 (31.0%) Urticaria, increased transaminase levels,
vomiting, diarrhoea,
Le et al (2006) 64 403 admissions 1060 Not reported in
publication
Not reported in publication
Leach (1998) 499 episodes 58 23 (39.6%) Vomiting, rash, diarrhoea, arthropathy,
neutropenia, nausea, fits
Mitchell (1979) 1669 children 280 Not reported in
publication
Not reported in publication
Maistrello (1999) 1103 children 59 24 (40.6%) Gasto-intestinal disorders,
Martinez-Mir (1996) 490 children 68 Not reported in
publication
Not reported in publication
Neubert (2004) 156 children 31 Not reported in
publication
Not reported in publication
Oshikoya (2007) 3821 children 27 12 (44.4%) Red man syndrome, pustular rash, stevens-
johnson syndrome, erythema, jaundice,
anaphylaxis, urticaria, fever
Shockrollah (2009) 230 children 5 2 (40%) Not reported in publication
Turner (1999) 936 episodes 157 34 (21.6%) Not reported in publication
Vazquez de la villa (1999) 597 children 26 9 (34.6%) Diarrhoea, vomiting, rash
Anti-epileptics
(n=14)
Choonara (1984) 268 children 15 7 (46.6%) Drowsiness, hyperactivity, ataxia
Dharnidharka (1993) 703 children 7 1 (14.2%) Skin rash
Dos Santos (2009) 3726 episodes 302 26 (8.6%) Not reported in publication
Easton Carter (2003b) 17432 episodes 41 Not reported in
publication
Not reported in publication
Gill (1995) 899 episodes 76 3 (3.9%) Not reported in publication
Gonzalez-Martin (1998) 219 children 46 5 (10.8%) Not reported in publication
Le et al (2006) 64 403 admissions 1060 Not reported in
publication
Not reported in publication
Leach (1998) 499 episodes 58 1 Apnoea
Mitchell (1979) 1669 children 280 Not reported in
publication
Not reported in publication
Martinez-Mir (1996) 490 children 68 Not reported in
publication
Not reported in publication
Neubert (2004) 156 children 31 Not reported in
publication
Not reported in publication
Oshikoya (2007) 3821 children 27 2 (7.4%) Erythema
Anti-epileptics
Table 5. Cont.
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Table 5. Cont.
In hospital studies
Telechea (2010) 123 children 46 15 (32.6%) Not reported in publication
Vazquez de la villa (1999) 597 children 26 4 (15.3%) Sedation, paradoxil reaction
Corticosteroids
(n =10)
Dos Santos (2006) 265 children 47 11 (23.4%) Not reported in publication
Gill (1995) 899 episodes 76 6 (7.8%) Not reported in publication
Gonzalez-Martin (1998) 219 children 46 3 (6.5%) Not reported in publication
Impicciatore (2002) 1619 children 29 1 (3.4%) Rash
Leach (1998) 499 episodes 58 1 (1.7%) Gastric irritation
Mitchell (1979) 1669 children 280 Not reported in
publication
Not reported in publication
Neubert (2004) 156 children 31 Not reported in
publication
Not reported in publication
Telechea (2010) 123 children 46 4 (8.6%) Not reported in publication
Turner (1999) 936 episodes 157 10 (6.3%) Not reported in publication
Vazquez de la villa (1999) 597 children 26 1 (3.8%) Cushing syndrome
Bronchodilators
(n =9)
Choonara (1984) 268 children 15 3 (20%) Tachycardia
Easton Carter (2003b) 17432 episodes 41 Not reported in
publication
Not reported in publication
Gill (1995) 899 episodes 76 8 (10.5%) Not reported in publication
Gonzalez-Martin (1998) 219 children 46 8 (17.3%) Not reported in publication
Impicciatore (2002) 1619 children 29 5 (17.2%) Tremor, tachycardia
Neubert (2004) 156 children 31 Not reported in
publication
Not reported in publication
Telechea (2010) 123 children 46 8 (17.3%) Not reported in publication
Turner (1999) 936 episodes 157 8 (5.0%) Not reported in publication
Vazquez de la villa (1999) 597 children 26 11 (42.3%) Tachycardia, nervousness, vomiting
Cytotoxics
(n =7
Dos Santos (2009) 3726 episodes 302 10 (3.3%) Not reported in publication
Gonzalez-Martin (1998) 219 children 46 7 (15.2%) Not reported in publication
Jonville-Bera (2002) 227 children 6 4 (66.6%) Vomiting
Cytotoxics
Le et al (2006) 64 403 admissions 1060 Not reported in
publication
Not reported in publication
Leach (1998) 499 episodes 58 1 (1.7%) Thrombocytopenia
Mitchell (1979) 1669 children 280 Not reported in
publication
Not reported in publication
Telechea (2010) 123 children 46 1 (2.1%) Not reported in publication
Diuretics
(n =6)
Easton Carter (2003b) 17432 episodes 41 Not reported in
publication
Not reported in publication
Leach (1998) 499 episodes 58 1 (1.7%) Over diereses
Mitchell (1979) 1669 children 280 Not reported in
publication
Not reported in publication
Neubert (2004) 156 children 31 Not reported in
publication
Not reported in publication
Telechea (2010) 123 children 46 9 (19.5%) Not reported in publication
Turner (1999) 936 episodes 157 31 (19.7%) Not reported in publication
Community
Anti-infectives
(n =13)
Cirko-Begovic (1989) 2459 children 63 49 (78%) Not reported in publication
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Table 5. Cont.
Community
Easton-Carter (2003a) 8601 consultations 118 Not reported in
publication
Not reported in publication
Horen (2002) 1419 consultations 20 9 (45%) Not reported in publication
Juntti-Patinen (2006) Not reported for
children
4 Not reported for
children only
Not reported for children only
Kaushal (2007) 1689 children 226 158 (70%) Nausea, vomiting and diarrhoea.
Kramer (1985) 4244 courses of
therapy
200 Not reported in
publication
Diarrhoea, other gastrointestinal
complaints and skin rashes
Menniti-Ippolito (2000) 7890 children 119 79 (66%) Cutaneous, gastrointestinal, eosinophilia,
neurological, angioedema, fever
Planchamp (2009) 12995 consultations 43 Not reported in
publication
Not reported in publication
Sanz (1987) 1327 children 10 4 (40%) Cutaneous reaction and diarrhoea
Munoz (1998) 47107 consultations 447 49.5% Included skin reactions
Jonville-Bera (2002) A&E: 428 children
Private paediatricians:
1192 children
A&E: 4
Private paediatricians:
8
A&E: 2 (50%)
Private
paediatricians: 6
(75%)
Diarrhoea, rash, vomiting
Anti-infectives
Woods (1987) 1590 children 235 40 (17%) Diarrhoea, drowsiness, rash, headache,
hyperactivity, anorexia, abdominal pain,
vomiting, sleep disturbance
Zahraoui (2010) Not reported 24 Not reported in
publication
Not reported in publication
NSAIDs
(n =6)
Kaushal (2007) 1689 children 226 2 (1%) Not reported in publication
Menniti-Ippolito (2000) 7890 children 119 3 (3%) Cutaneous, haematuria,
hypertranspiration
Munoz (1998) 47107 consultations 447 Not reported Not reported in publication
Planchamp (2009) 12995 consultations 43 Not reported in
publication
Not reported in publication
Sanz (1987) 1327 children 10 1 (10%) Not reported in publication
Woods (1987) 1590 children 235 9 (4%) Drowsiness, abdominal pain,
aggressiveness, vomiting
Analgesics
(n =5)
Kaushal (2007) 1689 children 226 1 (0.4%) Not reported in publication
Munoz (1998) 47107 consultations 447 Not reported in
publication
Not reported in publication
Planchamp (2009) 12995 consultations 43 Not reported in
publication
Not reported in publication
Woods (1987) 1590 children 235 11 (5%) Drowsiness, irritability, aggressiveness
Zahraoui (2010) Not reported 24 Not reported in
publication
Not reported in publication
Vaccines
(n =5)
Horen (2002) 1419 consultations 20 5 (25%) Not reported in publication
Jonville-Bera (2002) A&E: 428 children
Private:1192 children
A&E:4
Private:8
A&E: 1 (25%)
Private: 2 (25%)
A&E: rash
Private:fever
Menniti-Ippolito (2000) 7890 children 119 14 (12%) Not reported in publication
Munoz (1998) 47107 consultations 447 ? 9.2% Not reported in publication
Planchamp (2009) 12995 consultations 43 Not reported in
publication
Not reported in publication
Antihistamine
(n =4)
Cirko-Begovic (1989) 2459 children 63 2 (3%) Not reported in publication
Kaushal (2007) 1689 children 226 2 (1%) Not reported in publication
Menniti-Ippolito (2000) 7890 children 119 2 (2%) Not reported in publication
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Table 5. Cont.
Community
Woods (1987) 1590 children 235 46 (20%) Drowsiness, aggressiveness, dry mouth,
headache, irritability, diarrhoea
Bronchodilators
(n =3)
Kaushal (2007) 1689 children 226 16 (7%) Not reported in publication
Kramer (1985) 4244 courses of therapy 200 Not reported in
publication
Various manifestations of central nervous
stimulation
Woods (1987) 1590 children 235 ADRs 6 (3%) Hyperactivity, shakiness, dizziness,
irritability, sleep disturbance.
Steroid
(n =3)
Horen (2002) 1419 consultations 20 1 (0.05%) Not reported in publication
Kaushal (2007) 1689 children 226 12 (5%) Not reported in publication
Woods (1987) 1590 children 235 5 (2%) Abdominal pain, diarrhoea
Combined settings (causing admission & in hospital)
Anti-infectives
(n =2)
Haffner (2006) 703 admissions 101 Not reported in
publication
Not reported in publication
Speranza (2008) 173 children 24 10 (41.6%) Not reported in publication
Bronchodilators
(n =1)
Haffner (2006) 703 admissions 101 Not reported in
publication
Not reported in publication
Anti-epileptics
(n =2)
Haffner (2006) 703 admissions 101 Not reported in
publication
Not reported in publication
Speranza (2008) 173 children 24 4 (16.6%) Not reported in publication
Cardiovascular
(n =1)
Haffner (2006) 703 admissions 101 Not reported in
publication
Not reported in publication
Analgesics
(n =1)
Speranza (2008) 173 children 24 2 (8.3%) Not reported in publication
Anti-ulcer
(n =1)
Speranza (2008) 173 children 24 2 (8.3%) Not reported in publication
Psychotropic
(n =1)
Speranza (2008) 173 children 24 2 (8.3%) Not reported in publication
Combined settings (in hospital & community)
Anti-infectives
(n =1)
Kushwaha (1994) 20310 admissions 267 Not reported in
publication
Erythmatous maculopapular rash,
thrombophlebitis, erythema multiformae,
fixed drug reaction, urticaria, jaundice,
aplastic anaemia, thrombocytopaenia
purpura
Vaccines
(n =1)
Kushwaha (1994) 20310 admissions 267 Not reported in
publication
Nodular cyst in gluteal region, injection
abcess
NSAID
(n =1)
Kushwaha (1994) 20310 admissions 267 Not reported in
publication
Erythmatous maculopapular rash
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causality in individual cases of ADRs is required to establish
whether there is an association between the untoward clinical
event and the suspected drug [6]. The detection of ADRs depends
on the validity and reliability of the tests employed and if sensitive
methods are performed, in theory, all ADRs should be detected.
We found a third (31/102) of studies did not report which causality
assessment they used, with an additional six not using a recognised
algorithm. As a consequence there may be either an underesti-
mation or over estimation of ADRs in these studies. Over a third
of studies (34/102) assessed ADRs for the severity of the reactions;
just eight of which did not report any severe ADRs. Severe ADRs
were described as those that caused either death or were directly
life-threatening, caused hospital admission, prolonged hospitalisa-
tion or caused transfer to higher level of clinical care [113]. The
ability to classify ADRs by severity provides a mechanism for
clinicians to identify problem areas and implement interventions to
inform paediatric pharmacovigilance practice.
The absence of avoidability data was most noticeable in this
review; with only fourteen studies (14/102; 14%) providing
avoidability data. Therefore it is not possible to consider this
important aspect of drug safety in order to prevent future ADRs
[7]. Further studies are clearly required to determine which ADRs
are potentially avoidable. These studies could provide the
necessary data in order to enable clinicians to administer
medications in the safest and appropriate way.
The reporting quality of some of the included studies was poor,
which may have affected the results. Not all provided a clear
definition of the term ‘adverse drug reaction’; often insufficient
information was in the publication in order to determine whether
ADRs included medication or prescribing errors. ADR incidence
data were not always clearly described in the publications. In
many studies (n = 48/102) reporting was unclear regarding
whether the incidence rate was reported at the patient and/or
episode level and whether or not all children had been exposed to
a drug.
It is disappointing given the large number of studies we identified
which addressed this problem that most did not include these
important methodological aspects. We recommend researchers
should consider the approach which we have taken to assess the
quality of these studies, although we recognise that further work is
needed to develop a quality assessment tool which meets rigorous
standards of development. We recommend that future studies
provide information on the avoidability of ADRs; this may help in
the development of interventions to improve drug prescribing and
Table 5. Cont.
Combined settings (in hospital & community)
Analgesic
(n=1)
Kushwaha (1994) 20310 admissions 267 Not reported in
publication
Erythmatous maculopapular rash, urticaria
Steroid
(n=1)
Kushwaha (1994) 20310 admissions 267 Not reported in
publication
injection abscess
Combined settings (causing admission, in hospital & community)
Steroid
(n=1)
McKenzie (1973) 658 children 175 Not reported in
publication
Psychotic reaction, cushingoid syndrome,
cataracts, hypertension
Anti-infectives
(n=1)
McKenzie (1973) 658 children 175 Not reported in
publication
Rash, diarrhoea, facial flush, monilia, pain in
injection site
Cytotoxics
(n=1)
McKenzie (1973) 658 children 175 Not reported in
publication
Alopecia, peripheral neutitis, mouth ulcer,
injection site inflammation, leukopenia,
secondary infection
Note 1 patient in the Zahraoui (2010) study died (gastrointestinal bleeding and severe thrombocytopenia after prolonged anti-convulsant treatment.
Mitchell (1988) – 5 deaths (fever, vomiting, arrhythmia and cardiopulmonary arrest attributed to theophylline and erythromycin; cardiac arrest and hypernatremia
attributed to halothane and nitrous oxide pneumonia attributed to chemotherapy-induced immunosuppression; cardiotoxicity attributed to doxorubicin; candida
sepsis and meningitis attributed to chemotherapy-induced immunosuppression).
Yosselson-Superstine (1982) – 1 death (no detail provided).
doi:10.1371/journal.pone.0024061.t005
Table 6. Univariate meta-regression results for causing
admission and in hospital incidence rates.
Covariate OR (95% CI) P
Setting: Admission 1
Hospital 2.73 (0.93,8.03) 0.07
% Female patients 1.13 (0.91,1.40) 0.23
Mean age (years) 0.71 (0.39,1.27) 0.21
Mean/median number of drugs 1.49 (1.14,1.94) 0.01
% Oncology patients 1.15 (0.89,1.50) 0.25
doi:10.1371/journal.pone.0024061.t006
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monitoring. There are several outcomes that warrant further
investigation or require more detailed information to be collected.
Important risk factor data and the number of medications each
child received needs to be reported fully in order to explore possible
sources of heterogeneity between studies. Future studies need to use
clear, unambiguous terminology to describe how ADR incidence
rates are calculated. This would improve understanding of the
clinical relevance of individual study findings and allow comparisons
between studies for the purposes of systematic review, enabling
more robust conclusions and recommendations.
This review confirms previous studies which have shown ADRs
to be an significant problem in children and has highlighted
therapeutic classes of drugs most commonly associated with them.
We strongly recommend further work to address prescribing
practices in different settings and avoidability of ADRs is needed
to indicate how such ADRs may be prevented.
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